



**CERTIFICATE OF MAILING**

I hereby certify that this TRANSMITTAL is being deposited with the U.S. Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on this 21<sup>st</sup> day of October, 2003.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: \_\_\_\_\_

*Wendy A. Frick*

Customer Number

24024

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Hazen, et al.

Serial No.: 09/931,287

Filed: August 16, 2001

For: **DIAGNOSTIC METHODS FOR  
ASTHMA**

) Examiner: Nolan, Patrick J.  
)  
)

) Art Unit: 1644  
)  
)

) Attorney Docket No.: 26473/04195  
)  
)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Transmitted herewith are the following:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449;
3. 5 References; and
4. A Return Receipt Postcard.

It is believed that no further fee is required relating to the filing of this Supplemental Information Disclosure Statement. If this is not the case, the Patent Office is hereby authorized to charge any related fee to Deposit Account No. 03-0172. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: \_\_\_\_\_

*October 20, 2003*

By: \_\_\_\_\_

*Pamela A. Docherty*  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416



Customer Number

24024

**CERTIFICATE OF MAILING**

I hereby certify that this SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Bo x 1450, Alexandria, Virginia 22313-1450, on this 25<sup>th</sup> day of October, 2003.

Typed or Printed name of person signing this certificate:

Signed: Wendy A. Frick

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:  
Hazen, et al.

Serial No.: 09/931,287

Filed: August 16, 2001

For: **DIAGNOSTIC METHODS FOR  
ASTHMA**

) Examiner: Nolan, Patrick J.

) Art Unit: 1644

) Attorney Docket No.: 26473/04195

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits. Applicants wish to disclose the following information:

**REFERENCES**

- ☒ The Applicants wish to make of record the references listed on the attached Form PTO-1449. copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ Listed on the attached PTO form 1449 is information known to persons substantively involved in the preparation of the application identified above, and is not a representation that more pertinent information does not exist.
- ☒ The identification of any information herein is not intended to be, and should not be understood as being, an admission that such information, in fact, constitutes "prior art" within the meaning of applicable law. The "prior art" status of any information is a matter to be resolved during prosecution.

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.
- ☒ This information disclosure statement is being filed within three months of the filing of the within application and/or **prior to a first Office Action** on the merits being mailed.

**PETITION**

- ☒ Applicants hereby request consideration of the attached information.

**DEPOSIT ACCOUNT**

- ☐ A check is attached in the amount of \$ \_\_\_\_\_ required under 37 § 1.17(p).
- ☒ It is not believed that any fee is required relating to the filing of this information disclosure statement. If this is not the case, the patent office is hereby authorized to charge any related fee to **Deposit Account No. 03-0172**.

Respectfully submitted,

Date: October 20, 2003

By: Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416



Subst. Form PTO-1449

APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Atty. Docket No.: 26473/04195

Serial No.: 09/931,28

Applicant: Hazen, et al.

Filing Date: August 16, 2001

Group: 1644

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Dat
	AA						
	AB						
	AC						
	AD						

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translatio
	AE	1,008,594	October 27, 1965	GB			
	AF						
	AG						
	AH						
	AI						

## OTHER PRIOR ART

	AJ	Supplementary European Search Report dated February 13, 2002.
	AK	"3-Bromo and 3,5-Dibromotyrosine: potential markers for eosinophil-dependent injury in vivo" by Hazen, et al., <u>Free Radical Biology and Medicine</u> , Vol. 25, No. Supp. 1, November 1998 (1998-11), p. 209.
	AL	"3-Bromotyrosine and 3,5-Dibromotyrosine are major products of protein oxidation by eosinophil peroxidase potential markers for eosinophil-dependent tissue injury in vivo" by Wu, et al., <u>Biochemistry</u> , No. 39, 1999, pp. 3538-3548.
	AM	"Synthesis and specific tritium labelling of the behaviourally active octapeptide des-9-glycinamide-lysine-vasopressin in two different amino acid residues" by Keri, et al., <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , Vol. 15, 1978, pp. 163-168.
	AN	
	AO	
	AP	
	AQ	
	AR	

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.